Description: AVEO Pharmaceuticals, Inc., doing business as AVEO Oncology, operates as a cancer therapeutics company. The company engages in discovering, developing, and commercializing targeted cancer therapies using its Human Response Platform. Its principal product candidate is tivozanib, for which the company has filed a new drug application with the U.S. food and drug administration as a proposed indication for the treatment of patients with advanced renal cell carcinoma (RCC). The company's product pipeline also comprises TAURUS, which is in a Phase II clinical study for the treatment of RCC. In addition, its product pipeline includes Biomarker Assessment of Tivozanib in ONcology program, such as BATON-RCC, a Phase II exploratory biomarker study in patients with advanced RCC; BATON-CRC, a Phase II clinical trial for the first-line therapy in patients with advanced metastatic colorectal cancer; and BATON-BC, a Phase II clinical trial for the treatment of patients with locally recurrent or metastatic triple negative breast cancer. Further, the company has a pipeline of monoclonal antibodies, including Ficlatuzumab, a hepatocyte growth factor inhibitory antibody, which is in Phase II clinical stage for the treatment of non-small cell lung cancer; and AV-203, a monoclonal antibody that targets the ErbB3 receptor and is in Phase I clinical trial for the treatment of solid tumors. AVEO Pharmaceuticals, Inc. has strategic partnerships with Merck & Co., Inc; OSI Pharmaceuticals, Inc.; Kyowa Hakko Kirin; Astellas Pharma Inc.; and Biogen Idec, Inc. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is based in Cambridge, Massachusetts.
Home Page: www.aveooncology.com
AVEO Technical Analysis
30 Winter Street
Boston,
MA
02108
United States
Phone:
857 400 0101
Officers
| Name | Title |
|---|---|
| Mr. Michael P. Bailey | CEO, Pres & Director |
| Mr. Erick J. Lucera CFA, CPA | Chief Financial Officer |
| Mr. Michael Ferraresso | Chief Commercial Officer |
| Mr. Jeb Ledell | Chief Operating Officer |
| Dr. Emile Farhan Ph.D. | Sr. VP of Technical Operations |
| Ms. Danielle Holland | VP of Legal & Corp. Sec. |
| Mr. Kevin Peacock | Sr. VP of Marketing |
| Mr. David Crist | VP of Sales |
| Ms. Catherine DeRose | VP of HR |
| Ms. Lisa M. Bruneau | VP of Fin. & Treasurer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 48.0769 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 17.957 |
| Price-to-Sales TTM: | 5.4917 |
| IPO Date: | 2010-03-12 |
| Fiscal Year End: | December |
| Full Time Employees: | 114 |